HIFU for the treatment of difficult colorectal liver metastases with unsuitable indications for resection and radiofrequency ablation: a phase I clinical trial

Yang, Tong; Ng, Derry Minyao; Du, Nannan; He, Na; Dai, Xiaoyu; Chen, Ping; Wu, Feng; Chen, Bin; Fan, Xiaoxiang; Yan, Kun; Zhou, Xinfeng; Dong, Mingjun; Zheng, Zhi; Gu, Liang

doi:10.1007/s00464-020-07644-y

Cited by 23 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, HIFU has been increasingly used in the treatment of liver cancer [ 35 , 36 ]. Due to its characteristics, some studies including our previous studies have shown that HIFU can be used as a potential treatment option for patients with liver cancer but are contraindicated for either RFA or surgery [ 18 , 19 ]. In a previous study, we reported on 13 patients with colorectal liver metastases who were contraindicated for either resection or RFA and eventually received HIFU treatment.…”

Section: Discussionmentioning

confidence: 99%

“…The 2-year PFS was 16.7%, and the median PFS was 9 months. Notably, the 2-year OS was 77.8%, and the median OS time was 25 months [ 18 ]. However, the long-term prognosis of patients with either GCLM or colorectal liver metastases who underwent primary lesion resection combined with hepatectomy is significantly different.…”

Section: Discussionmentioning

confidence: 99%

“…In summary, it has a transducer with a diameter of 20 cm, a focal length of 16.5 cm, and an operating frequency of 1.0 MHz with a focal region of 3 × 3 × 8 mm. Refer to the previous study for operational details [ 18 ]. A treatment plan was devised with a 3-dimensional reconstruction of the tumor boundary with 5-mm-separated sections.…”

Section: Methodsmentioning

confidence: 99%

“…Previous studies have shown that HIFU treatment could treat, including but not limited to liver tumors and pancreatic cancer, and is associated with fewer serious adverse reactions [ 16 , 17 ]. According to our previous studies, HIFU treatment for primary liver cancer and colorectal liver metastases has achieved surprising positive results [ 18 , 19 ]. Therefore, we designed a prospective, propensity score matching study for patients with GCLM without evidence of extrahepatic metastases who were unable to undergo hepatectomy or RFA.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study

Zhou

Hong

et al. 2021

BMC Surg

Self Cite

View full text Add to dashboard Cite

Background The purpose of this study was to explore the efficacy and safety of high intensity focused ultrasound (HIFU) in gastric cancer with liver metastasis (GCLM) patients who were contraindicated for either hepatectomy or radiofrequency ablation (RFA). Methods This is a prospective, observational study on GCLM patients with 1–3 liver metastases. The primary gastric lesions were thoroughly resected and any case that exhibited extra-hepatic metastasis was excluded. A 1:2:2 propensity score-matching analysis was performed using a logistic regression model on the HIFU group, best supportive care (BSC) group, and palliative chemotherapy (PC) group. The primary endpoints include progression-free survival (PFS) and overall survival (OS). Results Forty patients were finally included, there were 8 cases in HIFU group, 16 cases in BSC group, and 16 cases in PC group. The median follow-up time for the entire cohort was 10 months. The median PFS was 16.5 months in HIFU group, 2 months in BSC group, and 5 months in PC group. The median OS was 27.5 months in the HIFU group, 7 months in the BSC group, and 11.5 months in the PC group. Additionally, no grade 3 or higher adverse events occurred in the HIFU group. Conclusion The results of this study showed that HIFU treatment could improve the long-term prognosis of GCLM patients without a significant increase in the occurrence of adverse events. Compared with PC and BSC, HIFU is the preferred treatment option when GCLM patients without extra-hepatic metastasis are unable to undergo either surgery or RFA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study

Zhou

Hong

et al. 2021

BMC Surg

Self Cite

View full text Add to dashboard Cite

show abstract

“…Adverse events (AE) occurred in 69.3% of patients with no grade 3–4 AEs. No osteonecrosis of the rib was noted [ 118 ].…”

Section: Local Ablative Therapiesmentioning

confidence: 99%

Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist

Torres-Jiménez

Esteban-Villarrubia

Ferreiro-Monteagudo

et al. 2021

Cancers

View full text Add to dashboard Cite

For patients with isolated liver metastases from colorectal cancer who are not candidates for potentially curative resections, non-surgical local treatments may be useful. Non-surgical local treatments are classified according to how the treatment is administered. Local treatments are applied directly on hepatic parenchyma, such as radiofrequency, microwave hyperthermia and cryotherapy. Locoregional therapies are delivered through the hepatic artery, such as chemoinfusion, chemoembolization or selective internal radiation with Yttrium 90 radioembolization. The purpose of this review is to describe the different interventional therapies that are available for these patients in routine clinical practice, the most important clinical trials that have tried to demonstrate the effectiveness of each therapy and recommendations from principal medical oncologic societies.

show abstract

The Emerging Landscape for Combating Resistance Associated with Energy‐Based Therapies via Nanomedicine

Hu,

Zuo,

Hsu

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Cancer represents a serious disease with significant implications for public health, imposing substantial economic burden and negative societal consequences. Compared to conventional cancer treatments, such as surgery and chemotherapy, energy‐based therapies (ET) based on athermal and thermal ablation provide distinct advantages, including minimally invasive procedures and rapid postoperative recovery. Nevertheless, due to the complex pathophysiology of many solid tumors, the therapeutic effectiveness of ET is often limited. Nanotechnology offers unique opportunities by enabling facile material designs, tunable physicochemical properties, and excellent biocompatibility, thereby further augmenting the outcomes of ET. Numerous nanomaterials have demonstrated the ability to overcome intrinsic therapeutic resistance associated with ET, leading to improved anti‐tumor responses. This comprehensive review systemically summarizes the underlying mechanisms of ET‐associated resistance (ETR) and highlights representative applications of nanoplatforms used to mitigate ETR. Overall, this review emphasizes the recent advances in the field and presents a detailed account of novel nanomaterial designs in combating ETR, along with efforts aimed at facilitating their clinical translation.This article is protected by copyright. All rights reserved

show abstract

HIFU for the treatment of difficult colorectal liver metastases with unsuitable indications for resection and radiofrequency ablation: a phase I clinical trial

Cited by 23 publications

References 35 publications

HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study

HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study

Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist

The Emerging Landscape for Combating Resistance Associated with Energy‐Based Therapies via Nanomedicine

Contact Info

Product

Resources

About